原发性小梁切除术与管分流术研究随访1年后的治疗结局
这项多中心随机临床试验纳入242眼药物无法控制且无眼部切口手术史的青光眼,比较350-mm² Baerveldt管分流与丝裂霉素C(MMC)小梁切除术的1年结局。小梁切除术组失败累积概率更低(7.9% vs 17.3%),眼压更低、用药更少,但严重并发症更多。
要点
- 小梁切除术组1年失败累积概率7.9%,低于管分流组的17.3%(P=0.01)。
- 1年时小梁切除术组平均眼压12.4 mmHg、用药0.9种,均低于管分流组。
- 管分流组严重并发症发生率1%,低于小梁切除术组的7%(P=0.03)。
核心结论
- 在PTVT研究中,随访1年时MMC小梁切除术的手术成功率高于管分流植入。
- 与管分流手术相比,MMC小梁切除术在随访第一年获得更低的眼压且使用更少的青光眼药物。
- 管分流手术后发生导致视力丧失或需要再手术的严重并发症的频率低于MMC小梁切除术。
研究设计与样本
- 多中心随机临床试验,纳入242例患者的242眼,其中管分流组125眼、小梁切除术组117眼。
- 患者来自16个临床中心,随机分配至350-mm² Baerveldt青光眼植入物管分流或MMC(0.4 mg/ml,2分钟)小梁切除术。
- 纳入对象为药物无法控制且无既往眼部切口手术史的青光眼患者。
主要发现
- 随访第一年失败累积概率管分流组为17.3%,小梁切除术组为7.9%(P=0.01;风险比2.59;95%置信区间1.20-5.60)。
- 1年时平均±标准差眼压管分流组为13.8±4.1 mmHg,小梁切除术组为12.4±4.4 mmHg(P=0.01)。
- 青光眼药物数量管分流组为2.1±1.4,小梁切除术组为0.9±1.4(P<0.001)。
- 术后并发症管分流组36例(29%),小梁切除术组48例(41%)(P=0.06)。
- 需要再手术或导致2行Snellen视力或以上丧失的严重并发症管分流组1例(1%),小梁切除术组8例(7%)(P=0.03)。
关键数值与推荐
- 失败定义:眼压超过21 mmHg或较基线降低不足20%、眼压5 mmHg或以下、因青光眼再手术、或丧失光感视力。
- 管分流组使用350-mm² Baerveldt青光眼植入物。
- 小梁切除术组使用MMC 0.4 mg/ml作用2分钟。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report 1-year treatment outcomes in the Primary Tube Versus Trabeculectomy (PTVT) Study. DESIGN: Multicenter, randomized clinical trial. PARTICIPANTS: Two hundred forty-two eyes of 242 patients with medically uncontrolled glaucoma and no previous incisional ocular surgery, including 125 in the tube group and 117 in the trabeculectomy group. METHODS: Patients were enrolled at 16 clinical centers and assigned randomly to treatment with a tube shunt (350-mm2 Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (MMC; 0.4 mg/ml for 2 minutes). MAIN OUTCOME MEASURES: Intraocular pressure (IOP), glaucoma medical therapy, visual acuity, visual fields, surgical complications, and failure (IOP of more than 21 mmHg or reduced by less than 20% from baseline, IOP of 5 mmHg or less, reoperation for glaucoma, or loss of light perception vision). RESULTS: The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60). Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001). Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06). Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03). CONCLUSIONS: Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study. Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up. The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.
引用
- Gedde SJ, Feuer WJ, Shi W, et al. Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 1 Year of Follow-up. Ophthalmology. 2018. PMID: 29477688. doi:10.1016/j.ophtha.2018.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。